McKesson Pharmacy Systems and Automation enables Rx delivery to patients anywhere
PITTSBURGH — McKesson Pharmacy Systems and Automation on Wednesday introduced a new EnterpriseRx Flexible Delivery solution that expands the reach of outpatient and retail pharmacies beyond their local communities. The new solution can be seen at the American Society of Health-System Pharmacists Midyear Clinical Meeting, which runs Dec. 8 to12.
“EnterpriseRx Flexible Delivery solution matches the convenience of a mail order program without compromising the personal connection a patient has with their hometown pharmacist, or the pharmacist who took the time to explain their medication at the end of a hospital visit,” Nathan Mott, President MPS & A said. “Whether a patient’s home is 30 or 300 miles away, the pharmacist who has an established relationship with the patient can still provide personal care.”
MPS & A customers currently using EnterpriseRx Flexible Delivery range from outpatient pharmacies operating specialty prescription programs and large retail chains staying connected with snow birds, to small independent pharmacies serving patients in rural communities.
Teva looks at effects of Copaxone patent loss
JERUSALEM — Teva Pharmaceutical Industries anticipates that it could lose about $500 million in sales next year if a generic version of its multiple sclerosis drug hits the market, the Israeli drug maker said Tuesday.
In issuing its financial outlook for the 2014 calendar year, Teva said it expected sales of about $19.3 billion to $20.3 billion if at least two generic versions of Copaxone (glatiramer acetate) hit the U.S. market in June, or $19.8 billion to $20.8 billion if they don’t. Mylan and Momenta Pharmaceuticals are among the companies hoping to launch a generic version of the drug, but Teva said its sales would see a $78 million benefit for every month the launch of a generic version was delayed.
"2014 will be a pivotal year for Teva and a year of major transitions across the company," acting president and CEO Eyal Desheh said. "We will continue to make significant progress in implementing our strategy."
Generic drugs, from which Teva derives most of its revenue, are expected to have overall sales of $9.8 billion to$10.5 billion. Copaxone had sales of $3.6 billion in 2012, according to IMS Health.
FDA advisory committee recommends approval for Takeda’s vedolizumab
DEERFIELD, Ill. — An expert panel at the Food and Drug Administration has given a thumbs-up to an experimental drug made by Takeda Pharmaceutical Co. for treating ulcerative colitis and Crohn’s disease, the drug maker said.
Takeda said the FDA’s Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committee voted in favor of approval for vedolizumab in adults with moderately to severely active UC or Crohn’s. A favorable advisory committee vote does not guarantee FDA approval of a drug, but the agency usually follows the votes when deciding whether or not to grant approval.
"People with ulcerative colitis or Crohn’s disease are in need of additional treatment options, as many patients lose response to currently available treatments," Takeda VP general medicine Asit Parikh said. "Vedolizumab was designed to treat inflammation of the [gastrointestinal] tract and, if approved, may offer an additional option for patients suffering from ulcerative colitis or Crohn’s disease."